Xceed’s vision is to advance molecular diagnostics and improve health outcomes by providing a cost-effective, automated system and services that facilitate the rapid translation of novel multiplexed genomic tests from research into routine clinical use. Our products comprise the ZiplexTM System for automated gene-expression analysis (available in the US and Canada for research use only), custom array services, and pre-configured arrays. Xceed is also developing multiplexed genomic tests for the Ziplex platform, both internally and with strategic partners. Xceed’s R&D and manufacturing are headquartered in Toronto, Ontario, with executive offices in Wellesley, Massachusetts. For more information, visit www.Xceedmolecular.com.
Xceed Molecular Corporation Secures US$3.0MM From MMV Financial Inc.